Profile data is unavailable for this security.
About the company
Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
- Revenue in EUR (TTM)3.57m
- Net income in EUR-17.36m
- Incorporated1996
- Employees11.00
- LocationNicox SADrakkar 2 - Batiment D2405 route des DolinesCS 10313 Sophia AntipolisVALBONNE 06560FranceFRA
- Phone+33 497245300
- Fax+33 497245399
- Websitehttp://www.nicox.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Auscann Group Holdings Ltd | 1.24m | -5.69m | 10.87m | 27.00 | -- | -- | -- | 8.79 | -0.0213 | -0.0217 | 0.0043 | 0.0162 | 0.1674 | -- | 5.35 | -- | -77.15 | -39.85 | -78.72 | -40.73 | 100.59 | -- | -460.74 | -925.91 | -- | -23.16 | 0.00 | -- | 13.88 | 51.37 | 57.10 | -- | -- | -- |
| Regent Pacific Group Ltd | 291.91k | -23.07m | 11.18m | 17.00 | -- | -- | -- | 38.31 | -0.8685 | -0.8685 | 0.011 | -0.053 | 0.0218 | -- | 12.19 | 145,566.40 | -172.08 | -50.00 | -694.26 | -59.04 | -- | -- | -7,901.89 | -2,685.21 | -- | -- | -- | -- | 574.47 | -44.72 | 31.24 | -- | -50.60 | -- |
| Advicenne SA | 2.94m | -7.03m | 11.21m | 20.00 | -- | -- | -- | 3.81 | -0.6728 | -0.6728 | 0.2805 | -0.9746 | 0.2207 | 4.41 | 2.22 | 147,100.00 | -52.73 | -57.86 | -129.08 | -89.10 | -104.21 | -327.56 | -238.99 | -513.56 | 0.9196 | -18.36 | 3.19 | -- | 25.67 | 25.03 | 38.70 | -- | 55.28 | -- |
| Guardion Health Sciences Inc | 11.11m | -4.72m | 11.32m | 9.00 | -- | 3.60 | -- | 1.02 | -4.00 | -4.00 | 9.49 | 2.66 | 0.9718 | 2.63 | 5.96 | 1,340,280.00 | -41.26 | -77.90 | -47.92 | -86.55 | 43.43 | 42.45 | -42.46 | -176.93 | 6.49 | -4.24 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| NicOx SA | 3.57m | -17.36m | 11.34m | 11.00 | -- | 0.1937 | -- | 3.17 | -0.3721 | -0.3721 | 0.0753 | 0.9128 | 0.0394 | -- | 1.83 | 324,909.10 | -19.13 | -19.22 | -21.35 | -20.78 | -- | -- | -485.70 | -370.14 | -- | -- | 0.3172 | -- | -54.78 | 7.25 | 36.57 | -- | -13.35 | -- |
| Acrux Ltd | 8.72m | -427.60k | 11.57m | 43.00 | -- | 3.39 | -- | 1.33 | -0.0024 | -0.0024 | 0.0502 | 0.0195 | 1.29 | -- | 4.86 | -- | -6.34 | -39.91 | -9.21 | -46.00 | 72.38 | -- | -4.90 | -132.53 | -- | -- | 0.2861 | -- | 133.74 | 28.29 | 92.23 | -- | -16.66 | -- |
| Cytophage Technologies Ltd | 0.00 | -5.16m | 11.63m | -- | -- | 2.69 | -- | -- | -0.6074 | -0.6074 | 0.00 | 0.121 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -463.03 | 0.2085 | -- | -- | -- | -25.88 | -- | -- | -- |
| Biofil Chemicals and Pharmaceuticals Ltd | 4.40m | 77.99k | 11.65m | -- | 147.89 | 5.82 | 95.54 | 2.65 | 0.44 | 0.44 | 25.11 | 11.19 | 1.02 | 20.08 | 1.50 | -- | 1.81 | 2.74 | 3.91 | 5.36 | 5.62 | 9.99 | 1.77 | 2.80 | 1.26 | 10.02 | 0.0235 | -- | 33.29 | 11.60 | 26.55 | 8.02 | -56.15 | -- |
| Medicamen Organics Ltd | 2.78m | 264.41k | 11.67m | 112.00 | 44.14 | 6.99 | 33.97 | 4.20 | 2.05 | 2.05 | 21.60 | 12.98 | -- | -- | -- | 2,256,402.00 | -- | -- | -- | -- | 42.12 | -- | 9.51 | -- | 0.9695 | 7.04 | 0.4546 | -- | 14.11 | -- | 91.93 | -- | -- | -- |
| Pila Pharma AB | 124.62k | -845.82k | 11.75m | 1.00 | -- | 20.72 | -- | 94.33 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
Data as of Jul 26 2024. Currency figures normalised to Nicox SA's reporting currency: Euro EUR
0.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Erasmus Gestion SASas of 28 Jun 2024 | 190.00k | 0.30% |
| Andbank Wealth Management SGIIC SAUas of 31 Dec 2023 | 43.30k | 0.07% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 0.00 | 0.00% |
| Apo Asset Management GmbHas of 30 Sep 2023 | 0.00 | 0.00% |
| Gestys SAas of 31 May 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 28 Jun 2024Source: FactSet Research Systems Inc.
